203 related articles for article (PubMed ID: 28034751)
1. MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells.
Guo ZP; Hu YC; Xie Y; Jin F; Song ZQ; Liu XD; Ma T; Zhou PK
Biochem Biophys Res Commun; 2017 Jan; 483(1):223-229. PubMed ID: 28034751
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
Jiang Y; Dai H; Li Y; Yin J; Guo S; Lin SY; McGrail DJ
Int J Cancer; 2019 Mar; 144(5):1092-1103. PubMed ID: 30152517
[TBL] [Abstract][Full Text] [Related]
3. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
Parrotta R; Okonska A; Ronner M; Weder W; Stahel R; Penengo L; Felley-Bosco E
J Thorac Oncol; 2017 Aug; 12(8):1309-1319. PubMed ID: 28389374
[TBL] [Abstract][Full Text] [Related]
4. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.
Lan H; Tang Z; Jin H; Sun Y
Sci Rep; 2016 Apr; 6():24218. PubMed ID: 27063292
[TBL] [Abstract][Full Text] [Related]
5. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Heerma van Voss MR; Brilliant JD; Vesuna F; Bol GM; van der Wall E; van Diest PJ; Raman V
Med Oncol; 2017 Mar; 34(3):33. PubMed ID: 28138868
[TBL] [Abstract][Full Text] [Related]
7. Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity.
Jia X; Li C; Li L; Liu X; Zhou L; Zhang W; Ni S; Lu Y; Chen L; Jeong LS; Yu J; Zhang Y; Zhang J; He S; Hu X; Sun H; Yu K; Liu G; Zhao H; Zhang Y; Jia L; Shao ZM
Clin Cancer Res; 2019 Jun; 25(12):3658-3672. PubMed ID: 30833270
[TBL] [Abstract][Full Text] [Related]
8. Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition.
Mattoo AR; Joun A; Jessup JM
Mol Cancer Res; 2019 Jan; 17(1):42-53. PubMed ID: 30201826
[TBL] [Abstract][Full Text] [Related]
9. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
[TBL] [Abstract][Full Text] [Related]
10. Overactivated neddylation pathway as a therapeutic target in lung cancer.
Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
[TBL] [Abstract][Full Text] [Related]
11. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
14. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
Lin ZP; Ratner ES; Whicker ME; Lee Y; Sartorelli AC
Mol Cancer Res; 2014 Mar; 12(3):381-393. PubMed ID: 24413181
[TBL] [Abstract][Full Text] [Related]
15. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Ji W; Weng X; Xu D; Cai S; Lou H; Ding L
Biochem Biophys Res Commun; 2020 Jan; 522(1):121-126. PubMed ID: 31753490
[TBL] [Abstract][Full Text] [Related]
16. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
17. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L
Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162
[TBL] [Abstract][Full Text] [Related]
18. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
[TBL] [Abstract][Full Text] [Related]
19. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
[TBL] [Abstract][Full Text] [Related]
20. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Mahdi H; Hafez N; Doroshow D; Sohal D; Keedy V; Do KT; LoRusso P; Jürgensmeier J; Avedissian M; Sklar J; Glover C; Felicetti B; Dean E; Mortimer P; Shapiro GI; Eder JP
JCO Precis Oncol; 2021; 5():. PubMed ID: 34527850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]